Nabriva Gains New CEO And Near-Market Antibiotic, Claims Leadership Role

The acquisition of Zavante Therapeutics and its late-stage investigational intravenous antibiotic for use in multi-drug resistant pathogens has also led to C-suite change at Nabriva Therapeutics.

SC1807_Tracks-Merged_335693570_1200.jpg
The acquisition will merge the product pipeline of the two companies. • Source: Shutterstock

Big pharma is increasingly reluctant to undertake the development of new antibiotics, but Nabriva Therapeutics PLC's acquisition of San Diego, CA-based Zavante Therapeutics Inc. and its last-stage investigational agent, Contepo (fosfomycin, intravenous), indicates that smaller biopharma companies may be benefiting from the trend.

The Zavante acquisition, announced July 24, strengthens Nabriva's late-stage pipeline and the company's growing role as a leader in the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.